Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals
#Acquisition #Partners
Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.
#Investment #Acquisition #Management Changes
Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft
#Customers #Partners
European Patent Office Grants Cellect Biotechnology Pivotal Patent for Stem Cells Activation
#Investment
Cellect Biotechnology Announces Exercise of Warrants for Cash Proceeds of Approximately $1.5 Million
#Investment
Cellect Biotechnology Announces Positive Data Demonstrating Robust Engraftment Using ApoGraft was Featured in Bone Marrow Transplantation;Primary Data Points Were Submitted to the FDA During Investigational New Drug Approval Process
#Investment
Cellect Biotechnology Continues to Achieve Milestones;Receives New Patent Allowance in Canada
#Partners #Expand
Barak's cannabis co Canndoc mulls merger with Cellect Bio
#Acquisition #Partners
Cellect Biotechnology Ltd. Prices $3m Registered Direct Offering of American Depositary Shares
#Investment
Cellect Biotechnology Receives Approval for U.S. Clinical Trial
#Partners #Investment
Cellect Announces Positive Phase I/II Mid-Study Results of Its ApoGraft™ Technology
#Customers #Partners
Cellect Announces Positive Results From Cell2in Collaboration Showing Significant Improvement in Expansion Rate and Function of Stem Cells
#Partners #Customers
Cellect Begins Collaboration with Washington University in Preparation for First U.S. Clinical Trial Using Cellect's ApoGraft™ for Bone Marrow Transplantations
#Partners
https://finance.yahoo.com/news/completion-manufacturing-clinical-grade-fasl-120000304.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuY2VsbGVjdC5jby9uZXdz&guce_referrer_sig=AQAAAIN38FbYnkSVwk3keB14T_oD_6Io3m1oVz3yUczu5Y7fUjr6pm6ZWYmBMeNOfXAwdw1Pxg_RE0ttUH57dqb__fu5yn_BIONvP_VfccK53c-ud8LCDxHGfEMwnUmXxD9jDscL0f4tlz0DqllND-4OoSBVMljx4yAmJbJz3cm-_LOM
undefined
Further to the Announcement of the Agreement Signed With the South Korean Cell2in: KORIL Approves Cellect's Grant Application
#Partners
Cellect Receives Multiple Patent Grants
#Partners #Customers
Cellect Announces a Major Technological Breakthrough for Industrialization of Apotainer™ Stem Cell Product Line
#Customers
Positive Results of Orthopedic Treatment With the Use of ApoGraft™ Enriched Stem Cells Derived From Fat Tissues
#Customers
Cellect Announces Positive Clinical Results
#Customers #Investment
Cellect Granted Key European Patent for Its Stem Cell Selection Technology
#Customers #Partners
Cellect Announces a Major Milestone for Enabling Stem Cells Production
#Customers #Investment
Cellect Biotechnology Announces $4 Million Registered Direct Offering
#Investment
Cellect Announces Opening of a Second Clinical Trial Site and Approval from Safety Board (DSMB) for Dose Escalation
#Partners
Cellect Announces Breakthrough Clinical Results
#Customers
Cellect Biotechnology Announces $4.3 Million Raise in a Registered Direct Offering
#Investment
Cellect raises $8.5m on Nasdaq at 13% discount
#Public Trading
Stem cell co Cellect files for Nasdaq offering
#Public Trading
Cellect Raises $2M For Stem Cell Therapy
#Investment #Public Trading
The stem-cell revolution targeting leukemia
#Investment